Analysis of rilotumumab data identifies a potential predictive biomarker for patients with gastric or gastroesophageal cancer
16 May 2012 | By Amgen
Exploratory biomarker analysis results...
List view / Grid view
16 May 2012 | By Amgen
Exploratory biomarker analysis results...
26 April 2012 | By Amgen
The FDA cannot approve the application in its present form...
25 April 2012 | By Amgen
Amgen and Mustafa Nevzat Pharmaceuticals have announced an agreement under which Amgen will acquire 95.6 percent of shares in MN...
23 April 2012 | By Amgen
Amgen has announced that George Rathmann, founding CEO of Amgen from 1980 to 1988 and board chairman until 1990, has passed away...
10 April 2012 | By Amgen
Amgen and KAI Pharmaceuticals have announced an agreement under which Amgen will acquire KAI...
4 April 2012 | By Amgen
The start of sclerostin antibody Phase 3 clinical trial program announced...
2 April 2012 | By Amgen
Collaboration comprises five monoclonal antibodies brodalumab (AMG 827) Phase 3 trial planned in 2012...
25 March 2012 | By Amgen
Robust AMG 145 Phase 2 program expected to deliver results in 2012...
2 March 2012 | By Amgen
Tender offer to acquire all outstanding shares of Micromet, Inc. - satisfied...
28 February 2012 | By Amgen
Amgen & European Schoolnet launched “Amgen Science Teacher Training Initiative”...
15 February 2012 | By Amgen
Amgen and Micromet entered into a Merger Agreement...
14 February 2012 | By Amgen
"Mike brings broad experience and immense expertise to his new role..."
8 February 2012 | By Amgen
Amgen to discuss the data from the sBLA for XGEVA® (denosumab)...
26 January 2012 | By Amgen
Amgen and Micromet, Inc. announced that the companies have entered into a definitive merger agreement...
29 December 2011 | By Amgen
FDA has invited Amgen to participate in a meeting of the ODAC on Feb. 8, 2012 to discuss the sBLA for XGEVA® (denosumab)...